Dengue Vaccines

Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.

Also Known As:

Dengue Vaccine, Tetravalent; Vaccine, Dengue; Vaccine, Dengvaxia; Vaccine, Tetravalent Dengue; Vaccines, Dengue; Dengue Tetravalent Vaccine, Live; Dengue Vaccine; Dengvaxia; Dengvaxia Vaccine; Tetravalent Dengue Vaccine

Networked: 502 relevant articles (60 outcomes, 124 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Viral Vaccines: 462
      - Dengue Vaccines: 502
        CYD-TDV vaccine: 14

Experts

1.	Guy, Bruno: 22 articles (01/2021 - 09/2004)
2.	Bonaparte, Matthew: 18 articles (01/2022 - 01/2016)
3.	Noriega, Fernando: 18 articles (01/2022 - 01/2015)
4.	Wilder-Smith, Annelies: 17 articles (01/2021 - 07/2008)
5.	Halstead, Scott B: 16 articles (01/2022 - 01/2005)
6.	Thomas, Stephen J: 16 articles (01/2021 - 01/2009)
7.	Bouckenooghe, Alain: 15 articles (01/2022 - 10/2014)
8.	Durbin, Anna P: 15 articles (01/2022 - 09/2011)
9.	Lang, Jean: 14 articles (01/2018 - 02/2004)
10.	Zambrano, Betzana: 13 articles (01/2022 - 01/2011)

Related Diseases

1.	Dengue (Dengue Fever) 01/01/2021 - "Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries." 01/01/2019 - "Unfortunately, there is no effective treatment for dengue, and the most popular dengue vaccine does not exhibit good curative effects. " 03/16/2016 - "The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model." 01/01/2016 - "Two large-scale efficacy studies with the recombinant yellow fever-17D-dengue virus, live-attenuated, tetravalent dengue vaccine (CYD-TDV) candidate undertaken in Asia (NCT01373281) and Latin America (NCT01374516) demonstrated significant protection against dengue disease during two years' active surveillance (active phase). " 01/01/2018 - "Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease."
2.	Infections 01/01/2020 - "It is important to confirm the accurate correlate of protection against DENV infection, and also to have other anti-dengue vaccine formulations licensed for use." 01/01/2016 - "The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection." 01/01/2017 - "This information together with in-depth studies on polyclonal sera and B-cells following natural DENV infection has tremendous implications for better immunogen design for a safe and effective dengue vaccine. " 10/01/2019 - "Collectively, the results from this study reveal the humoral and cellular immune responses and the protective effects conferred by DJ NS1 and NS3 immunization in the mouse model of DENV infection and provide a potential strategy for dengue vaccine design." 12/01/2004 - "In this context, a safe dengue vaccine that confers long-lasting protection against infection with the four dengue viruses is urgently required. "
3.	Severe Dengue 10/01/2019 - "Dengvaxia confers high protection against severe dengue in seropositive vaccinees. " 09/01/2022 - "Overall, our study shows that the dengue vaccines CYD-TDV and TAK-003 confer protection against severe dengue in children. " 09/01/2022 - "This study is a systematic review of the current literature realized to evaluate the efficacy of the dengue vaccines in preventing severe dengue in children. " 09/01/2022 - "Efficacy of Dengue Vaccines in the Prevention of Severe Dengue in Children: A Systematic Review." 10/01/2019 - "The first dengue virus vaccine, Dengvaxia, now licensed in 20 endemic countries, the EU and the USA, provides protection against severe dengue in seropositive individuals but increases the risk for naive recipients to develop severe dengue and to be hospitalised. "
4.	Yellow Fever 11/01/2012 - "Chimeric yellow fever 17D/DENV-1-4 viruses (CYD-1-4) have been developed as a tetravalent dengue vaccine candidate which is currently being evaluated in efficacy trials in Asia and America. " 09/07/2012 - "Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru." 01/01/2018 - "Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine." 03/29/2016 - "Protective and immunological behavior of chimeric yellow fever dengue vaccine." 05/01/2014 - "The chimeric yellow fever bone-based live attenuated dengue vaccine is furthest in development, but initial efficacy results have been disappointing. "
5.	Viremia 03/27/2020 - "This review compares the viremia kinetics and antibody responses of cynomolgus macaques (Macaca fasicularis), common marmosets (Callithrix jacchus), and tamarins (Saguinus midas and Saguinus labitus) and summarize the perspectives and the usefulness along with challenges in dengue vaccine development." 10/01/2011 - "Prior exposure to YF or monovalent dengue vaccines had no adverse effects on the safety or incidence of viremia associated with this TDV, but it increased immunogenicity." 04/01/2009 - "We conclude that green monkeys develop viremia and antibody responses and therefore provide a potential model for the preclinical evaluation of novel candidates for dengue vaccines." 06/08/2009 - "A simple method for evaluating dengue vaccine effectiveness in mice based on levels of viremia caused by intraperitoneal injection of infected culture cells." 04/01/2009 - "In this study we examined the capacity of green monkeys (Chlorocebus aethiops sabaeus) to develop dengue viremia, and thus provide a potential model for dengue vaccine testing. "

Related Drugs and Biologics

1.	Dengue Vaccines
2.	Vaccines
3.	Neutralizing Antibodies
4.	Epitopes
5.	Antibodies
6.	Immunoglobulin G (IgG)
7.	RNA (Ribonucleic Acid)
8.	Synthetic Vaccines (Recombinant Vaccines)
9.	Antiviral Agents (Antivirals)
10.	Insecticides

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Mosquito Nets
4.	Intraperitoneal Injections